Companies › Theriva Biologics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) Oncolytic adenovirus engineered to express GMCSF | – | Phase 1 | Pancreas Cancer, Metastatic | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07701486 | VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) | Phase 1 | Pancreas Cancer, Metastatic | Oncology | Aug 2027 |
Cash of $11m on 2026-06-30; operating cash outflow about $11m a year; runway about 12 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.